BDBM3535 | 171744-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: BDBM3535
• 英文别名: 4-(3-bromoanilino)-6-methylaminoquinazoline；4-N-(3-bromophenyl)-6-N-methylquinazoline-4,6-diamine
• CAS: 171744-96-0
• 化学式: C₁₅H₁₃BrN₄
• 分子量: 329.199
• InChiKey: KFBKCZIAECRELC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  BDBM3535 在 nitrosonium tetrafluoroborate 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成 1-[4-(3-Bromoanilino)quinazolin-6-yl]-3-(2-chloroethyl)-1-methyl-3-nitrosourea
  参考文献：
  名称：

  The Combi-Targeting Concept:  Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)

  摘要：

  According to the "combi-targeting" concept, the EGFR tyrosine kinase ( TK) inhibitory potency of compounds termed "combi-molecules" is critical for selective growth inhibition of tumor cells with disordered expression of EGFR or its closest family member erbB2. Here we report on the optimization of the EGFR TK inhibitory potency of the combi-molecules of the nitrosourea class by comparison with their aminoquinazoline and ureidoquinazoline precursors. This led to the discovery of a new structural parameter that influences their EGFR TK inhibitory potency, i.e., the torsion angle between the plane of the quinazoline ring and the ureido or the nitrosoureido moiety of the synthesized drugs. Compounds ( 3'-Cl and Br series) with small angles ( 0.5-3 degrees) were generally stronger EGFR TK inhibitors than those with large angles ( 18-21 degrees). This was further corroborated by ligand-receptor van der Waals interaction calculations that showed significant binding hindrance imposed by large torsion angles in the narrow ATP cleft of EGFR. Selective antiproliferative studies in a pair of mouse fibroblast NIH3T3 cells, one of which NIH3T3/neu being transfected with the erbB2 oncogene, showed that IC50 values for inhibition of EGFR TK could be good predictors of their selective potency against the serum-stimulated growth of the erbB2-tranfected cell line ( Pearson r = 0.8). On the basis of stability ( t(1/2)), EGFR TK inhibitory potency ( IC50), and selective erbB2 targeting, compound 23, a stable nitrosourea, was considered to have the structural requirements for further development.

  DOI：

  10.1021/jm0600390
• 作为产物：
  描述：

  2-氰基-4-硝基苯胺 在 吡啶 、 lithium aluminium tetrahydride 、 铁粉 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 3.5h， 生成 BDBM3535
  参考文献：
  名称：

  The Combi-Targeting Concept:  Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)

  摘要：

  According to the "combi-targeting" concept, the EGFR tyrosine kinase ( TK) inhibitory potency of compounds termed "combi-molecules" is critical for selective growth inhibition of tumor cells with disordered expression of EGFR or its closest family member erbB2. Here we report on the optimization of the EGFR TK inhibitory potency of the combi-molecules of the nitrosourea class by comparison with their aminoquinazoline and ureidoquinazoline precursors. This led to the discovery of a new structural parameter that influences their EGFR TK inhibitory potency, i.e., the torsion angle between the plane of the quinazoline ring and the ureido or the nitrosoureido moiety of the synthesized drugs. Compounds ( 3'-Cl and Br series) with small angles ( 0.5-3 degrees) were generally stronger EGFR TK inhibitors than those with large angles ( 18-21 degrees). This was further corroborated by ligand-receptor van der Waals interaction calculations that showed significant binding hindrance imposed by large torsion angles in the narrow ATP cleft of EGFR. Selective antiproliferative studies in a pair of mouse fibroblast NIH3T3 cells, one of which NIH3T3/neu being transfected with the erbB2 oncogene, showed that IC50 values for inhibition of EGFR TK could be good predictors of their selective potency against the serum-stimulated growth of the erbB2-tranfected cell line ( Pearson r = 0.8). On the basis of stability ( t(1/2)), EGFR TK inhibitory potency ( IC50), and selective erbB2 targeting, compound 23, a stable nitrosourea, was considered to have the structural requirements for further development.

  DOI：

  10.1021/jm0600390

文献信息

• Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor
  作者：Alexander J. Bridges、Hairong Zhou、Donna R. Cody、Gordon W. Rewcastle、Amy McMichael、H. D. Hollis Showalter、David W. Fry、Alan J. Kraker、William A. Denny

  DOI：10.1021/jm9503613

  日期：1996.1.1

  4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (32, PD 153035) is a very potent inhibitor (IC50 0.025 nM) of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), binding competitively at the ATP site. Structure-activity relationships for close analogues of 32 are very steep. Some derivatives have IC(50)s UP to 80-fold better than predicted from simple additive binding energy arguments, yet analogues possessing combinations of similar phenyl and quinazoline substituents do not show this ''supra-additive'' effect. Because some substituents which are mildly deactivating by themselves can be strongly activating when used in the correct combinations, it is proposed that certain substituted analogues possess the ability to induce a change in the conformation of the receptor when they bind. There is some bulk tolerance for substitution in the 6- and 7-positions of the quinazoline, so that 32 is not the optimal inhibitor for the induced conformation. The diethoxy derivative 56 [4-(3-bromoanilino)-6,7-diethoxyquinazoline] shows an IC50 Of 0.006 nM, making it the most potent inhibitor of the tyrosine kinase activity of the EGFR yet reported.
• The Combi-Targeting Concept:  Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)
  作者：Juozas Domarkas、Fabienne Dudouit、Christopher Williams、Qiu Qiyu、Ranjita Banerjee、Fouad Brahimi、Bertrand Jacques Jean-Claude

  DOI：10.1021/jm0600390

  日期：2006.6.1

  According to the "combi-targeting" concept, the EGFR tyrosine kinase ( TK) inhibitory potency of compounds termed "combi-molecules" is critical for selective growth inhibition of tumor cells with disordered expression of EGFR or its closest family member erbB2. Here we report on the optimization of the EGFR TK inhibitory potency of the combi-molecules of the nitrosourea class by comparison with their aminoquinazoline and ureidoquinazoline precursors. This led to the discovery of a new structural parameter that influences their EGFR TK inhibitory potency, i.e., the torsion angle between the plane of the quinazoline ring and the ureido or the nitrosoureido moiety of the synthesized drugs. Compounds ( 3'-Cl and Br series) with small angles ( 0.5-3 degrees) were generally stronger EGFR TK inhibitors than those with large angles ( 18-21 degrees). This was further corroborated by ligand-receptor van der Waals interaction calculations that showed significant binding hindrance imposed by large torsion angles in the narrow ATP cleft of EGFR. Selective antiproliferative studies in a pair of mouse fibroblast NIH3T3 cells, one of which NIH3T3/neu being transfected with the erbB2 oncogene, showed that IC50 values for inhibition of EGFR TK could be good predictors of their selective potency against the serum-stimulated growth of the erbB2-tranfected cell line ( Pearson r = 0.8). On the basis of stability ( t(1/2)), EGFR TK inhibitory potency ( IC50), and selective erbB2 targeting, compound 23, a stable nitrosourea, was considered to have the structural requirements for further development.
• Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides
  作者：Caterina Carmi、Elena Galvani、Federica Vacondio、Silvia Rivara、Alessio Lodola、Simonetta Russo、Stefania Aiello、Fabrizio Bordi、Gabriele Costantino、Andrea Cavazzoni、Roberta R. Alfieri、Andrea Ardizzoni、Pier Giorgio Petronini、Marco Mor

  DOI：10.1021/jm201507x

  日期：2012.3.8

  Irreversible epidermal growth factor receptor (EGFR) inhibitors contain a reactive warhead which covalently interacts with a conserved cysteine residue in the kinase domain. The acrylamide fragment, a commonly employed warhead, effectively alkylates Cys797 of EGFR, but its reactivity can cause rapid metabolic deactivation or nonspecific reactions with off-targets. We describe here a new series of irreversible inhibitors containing a 3-aminopropanamide linked in position 6 to 4-anilinoquinazoline or 4-anilinoquinoline-3-carbonitrile driving portions. Some of these compounds proved to be as efficient as their acrylamide analogues in inhibiting EGFR-TK (TK = tyrosine kinase) autophosphorylation in A549 lung cancer cells. Moreover, several 3-aminopropanamides suppressed proliferation of gefitinib-resistant H1975 cells, harboring the T790M mutation in EGFR, at significantly lower concentrations than did gefitinib. A prototypical compound, N-(4-(3-bromoanilino)quinazolin-6-yl)-3-(dimethylamino)propanamide (5), did not show covalent binding to cell-free EGFR-TK in a fluorescence assay, while it underwent selective activation in the intracellular environment, releasing an acrylamide derivative which can react with thiol groups.